Eurofins Viracor Opens Expansive Laboratory in Lenexa, KS
Lenexa, KS, [October 6, 2022] – Eurofins Viracor, a leader in infectious disease and immunology testing, today celebrated the opening of its expansive new laboratory in Lenexa, KS. The 110,000 square foot, state-of-the-art facility will be home to 450 employees, comprised of 215 current employees and 235 newly created roles and creates additional capacity to support growth in b ...
Eurofins Viracor launches Epstein-Barr Virus (EBV) inSIGHT™ to Evaluate T Cell Mediated Immunity to Epstein-Barr Virus
Eurofins Viracor, a leader in infectious disease and immunology testing, launches a functional T Cell test to measure CD4 and CD8 Epstein-Barr virus-specific T cell immune response. The test joins the innovative inSIGHT diagnostic portfolio of virus-specific cell mediated immunity tests offered by Viracor. EBV is a common risk factor for post-transplant lymphoproliferative diso ...
Third Circuit Court of Appeals Affirms Judgment in Favor of Eurofins Viracor in Patent Infringement Case
Eurofins Viracor, a leader in infectious disease, immunology, and allergy testing, announced today that the Third Circuit of the Federal Court of Appeals affirmed the U.S. District Court for the District of Delaware’s entry of judgment in Eurofins Viracor’s favor that the patent asserted in CareDx’s patent infringement case against Eurofins Viracor is invalid. Eurofins Viracor ...
Eurofins Viracor and Cornell University Sign Exclusive Licensing Agreement to Expand Access to Ground-Breaking Technologies for Assessing Organ and Tissue Damage in Transplant and COVID-19 Patients
Blood and urine-based cell-free DNA detection methods will provide healthcare practitioners with highly accurate, non-invasive tools to identify and monitor for infection, rejection, and severity of organ damage in transplant and COVID-19 patients. Eurofins Viracor, LLC, a leader in testing for infectious disease, immunology, and allergy, announced today that it has entered int ...
Yahoo! Finance - Eurofins & Transplant Genomics Launch OmniGraf™ Kidney Rejection Biomarker
OmniGraf™ – the first and only rejection assay on the market that combines the power of gene expression profiling (TruGraf®) and donor-derived cell-free DNA (Viracor TRAC®) in one non-invasive, easy-to-draw test. OmniGraf offers the highest positive predictive value (PPV) and negative predictive value (NPV) of any kidney test available, empowering clinicians and patients to make the best possible treatment decisions with the goal of improving long-term graft outcomes.
360 Dx - Eurofins Viracor Test Measures T-Cell Response to Determine COVID-19 Immunity
NEW YORK – While vaccines for SARS-CoV-2 have rolled out at home and abroad, there is still uncertainty about their long-term effectiveness against the virus, and questions linger about whether a booster shot will be necessary and how often individuals will need to get vaccinated to remain protected against the virus. Against this backdrop Eurofins Viracor has developed a test ...
Eurofins Viracor Invests in Innovation with the Launch of Coronavirus (COVID-19) SARS-CoV-2 inSIGHT™ T Cell Immunity Testing
As one of the first commercial labs to deliver COVID-19 testing, Eurofins Viracor, Inc. continues to invest in innovation with the launch of Coronavirus SARS-CoV-2 inSIGHT™ T Cell Immunity testing. Viracor’s inSIGHT™ T Cell Immunity test delivers a deeper understanding of a patient's response to viral antigens and gives healthcare providers critical insight to aid in treatment ...
Eurofins' US Transplant Diagnostics and Cleveland Clinic Sign a Licensing Agreement to Expand Access to an Innovative, Novel Biomarker for Detecting Rejection in Kidney Transplant Patients
Urine biomarker test will provide healthcare practitioners with a highly accurate, non-invasive tool to identify and monitor rejection and elevated risk of rejection in kidney transplant patients.
Eurofins U.S. Clinical Diagnostic Laboratories Partner with Insurance Providers to Cover FDA-Authorized At-Home COVID-19 Test
Eurofins announces that its FDA-authorized At-Home COVID-19 Nasal PCR Test is now being covered by Medicare, Medicaid and commercial insurance providers. The Emergency Use Authorization ("EUA") authorized self-collection kit gives consumers a minimally invasive, convenient and quick option to test from the comfort of their home. Results are provided via email link within 24 hours of sample receipt.
ESPN - Inside the complex choreography of COVID-19 testing that keeps tournaments running
The vials are ready to leave at 2:30 p.m. from Portland, Oregon. It's mid-September, five days before the Cambia Portland Classic LPGA tournament begins, and a highly choreographed maneuver, as complex as anything else in the tournament, is about to take place. The vials containing oral or nasal swab samples from players, are part of a big goal: to get LPGA athletes tested for COVID-19 in record time so they can be cleared for each tournament.